Cargando…
Results of a phase 1/2 study of cemdisiran in healthy subjects and patients with paroxysmal nocturnal hemoglobinuria
Complement dysregulation underpins the physiopathology of paroxysmal nocturnal hemoglobinuria (PNH). Cemdisiran, an RNA interference investigational treatment, silences complement component 5 (C5) expression in the liver. Previously reported results showed sustained reduction in C5 levels following...
Autores principales: | Gaya, Anna, Munir, Talha, Urbano‐Ispizua, Alvaro, Griffin, Morag, Taubel, Jorg, Bush, Jim, Bhan, Ishir, Borodovsky, Anna, Wang, Yue, Badri, Prajakta, Garg, Pushkal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10435727/ https://www.ncbi.nlm.nih.gov/pubmed/37601837 http://dx.doi.org/10.1002/jha2.748 |
Ejemplares similares
-
A phase III, randomised, double‐blind, multi‐national clinical trial comparing SB12 (proposed eculizumab biosimilar) and reference eculizumab in patients with paroxysmal nocturnal haemoglobinuria
por: Jang, Jun Ho, et al.
Publicado: (2022) -
Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria
por: Badri, Prajakta, et al.
Publicado: (2020) -
Correction to: Pharmacokinetic and Pharmacodynamic Properties of Cemdisiran, an RNAi Therapeutic Targeting Complement Component 5, in Healthy Subjects and Patients with Paroxysmal Nocturnal Hemoglobinuria
por: Badri, Prajakta, et al.
Publicado: (2022) -
Acute kidney injury in Jamaicans with sickle cell disease hospitalized with COVID‐19 infection
por: Fisher, Lori‐Ann, et al.
Publicado: (2023) -
Impact of age‐dependent red blood cell parameters on α‐globin gene genotyping in children
por: Nissen, Peter H., et al.
Publicado: (2022)